Payment overview · 2025
General Payments
$52.89
3 reported records · 3 companies
Healthcare provider profile · identity verified
Ross Arthur Stemmler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WILMINGTON, NC · NPI 1164816559
Verified facts
What the public records show
CMS Open Payments records show Ross Arthur Stemmler, MD received $52.89 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.17 | 45.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.20 | 28.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.52 | 25.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.89 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 487 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 105 |
| Lisinopril | Lisinopril | 396 | 116 |
| Losartan Potassium | Losartan Potassium | 313 | 83 |
| Omeprazole | Omeprazole | 308 | 84 |
| Trazodone Hcl | Trazodone Hcl | 265 | 69 |
| Gabapentin | Gabapentin | 218 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 54 |
| Metformin Hcl | Metformin Hcl | 199 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 47 |
| Alprazolam | Alprazolam | 165 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 49 |
| Furosemide | Furosemide | 149 | 43 |
| Simvastatin | Simvastatin | 146 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 37 |
| Meloxicam | Meloxicam | 125 | 35 |
| Sertraline Hcl | Sertraline Hcl | 124 | 32 |
| Montelukast Sodium | Montelukast Sodium | 121 | 40 |
| Allopurinol | Allopurinol | 114 | 33 |
| Potassium Chloride | Potassium Chloride | 111 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 25 |
| Glipizide Er | Glipizide | 97 | 24 |
| Ozempic | Semaglutide | 97 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 29 |
| Glipizide | Glipizide | 92 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 21 |
| Carvedilol | Carvedilol | 74 | 20 |
| Bupropion Xl | Bupropion Hcl | 73 | 27 |
| Eliquis | Apixaban | 73 | 19 |
| Finasteride | Finasteride | 59 | 17 |
| Spironolactone | Spironolactone | 59 | 15 |
| Famotidine | Famotidine | 55 | 17 |
| Glimepiride | Glimepiride | 55 | 17 |
| Mirtazapine | Mirtazapine | 55 | 13 |
| Prednisone | Prednisone | 55 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 20 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 41 |
| Valsartan | Valsartan | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Memantine Hcl | Memantine Hcl | 42 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Jardiance | Empagliflozin | 40 | 11 |
| Ibuprofen | Ibuprofen | 39 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 31 |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 27 |
| Estradiol | Estradiol | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Ramipril | Ramipril | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.89 · 3 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, MOUNJARO, PREVNAR 20, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error